A promising path to fighting COVID and other coronaviruses may have been based on a serious mistake. Scientists had zeroed in ...

The COVID pandemic illustrated how urgently we need antiviral medications capable of treating coronavirus infections. To aid ...

Sushmi Dey ...

A new SARS-CoV-2 variant, NB.1.8.1, may now account for more than one-third of all COVID-19 cases in the US, health officials say.

Targeting Spike protein fusion dynamics for Broad Spectrum efficacy against SARS-CoV2. Credit: Frontiers in Molecular Biosciences (2025). DOI: 10.3389/fmolb.2025.1575747 ...

Weight loss drugs like Ozempic and Wegovy are used by over 15 million adults in the U.S., or 4.5% of the population. Despite their effectiveness, they have drawbacks. Their effect may not last ...

Dive Brief: The Food and Drug Administration has approved a new oral medication for an uncommon kind of tumor, clearing Nuvation Bio’s Ibtrozi on Wednesday for certain people whose metastatic ...

SARS-CoV-2 vaccines reduce the risk of COVID-19.1–3 However, some disease-modifying anti-rheumatic drugs (DMARDs), particularly glucocorticoids, methotrexate, mycophenolate mofetil and rituximab, may ...

SARS-CoV-2 is the agent responsible for acute respiratory disease COVID-19 and the global pandemic initiated in early 2020. While the record-breaking development of vaccines has assisted the control ...

Otsuka Pharmaceutical has shared more detailed data behind its kidney disease drug’s phase 3 win, showing the monoclonal antibody halved patients’ urine protein-to-creatinine ratio (UPCR) levels.

We then assessed the properties of NB.1.8.1 by virological experiments. A lentivirus-based pseudovirus assay showed that the infectivity of NB.1.8.1 was significantly higher (2·5-fold; p<0·0001) than ...